Biotech Values

[DewDiligence]

NVO starts phase-3_trial_of CagriSema vs LLY’s Zepbound* in_non-diabetic_patients_with_BMI>=30:

https://clinicaltrials.gov/study/NCT06131437

CagriSema is a fixed-dose-combination of Cagrilintide, an amylin analogue, and 2.4mg Wegovy, dosed weekly by subcutaneous injection. I.e., CagriSema has a dual MoA that is different from any approved weight-loss drug.

In the phase-3 trial, the comparator arm is 15mg of weekly Zepbound*, the highest FDA-approved dose. The primary endpoint is % weight loss relative to baseline at 72 weeks.

*a/k/a Mounjaro (#msg-173180704).